Pfizer's $10B Metsera bid faces Novo Nordisk challenge

Technology Nov 07, 2025

Pfizer is trying to buy Metsera for $10 billion to get ahead in the booming weight-loss drug market, which could mean a big payday for Metsera's co-founders.
But things just got interesting—Novo Nordisk swooped in with an even bigger offer, sparking a legal fight as Pfizer accuses Novo of challenging their deal.

Metsera's weight-loss treatments and market potential

Metsera has been making waves with its new weight-loss treatments, showing promising results—up to 14% average weight loss in trials.
Experts think their drugs could bring in over $5 billion a year, and with the obesity drug market expected to top $100 billion by 2030, it's no wonder these pharma giants are going all-in.